Anti-TNF Therapy Is Emerging as the Primary Treatment Modality in Pediatric Inflammatory Bowel Disease

A population-based Canadian study found an increasing trend in utilization of anti-tumor necrosis factor agents in pediatric inflammatory bowel disease (IBD), also reporting that immunomodulator use is on the decline. This accompanying editorial discusses this emerging trend occurring in pediatric IBD world-wide. Data from the Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children with Crohn's Disease (RISK) study are presented and confirm the same trend among pediatric IBD in the United States.